# A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation

> **NCT04691648** · — · COMPLETED · sponsor: **Astellas Pharma Korea, Inc.** · enrollment: 33 (actual)

## Conditions studied

- Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

## Interventions

- **DRUG:** Gilteritinib Exposure

## Key facts

- **NCT ID:** NCT04691648
- **Lead sponsor:** Astellas Pharma Korea, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-17
- **Primary completion:** 2025-05-04
- **Final completion:** 2025-05-04
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04691648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04691648, "A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04691648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*